AMB-051 is under clinical development by AmMax Bio and currently in Phase II for Tenosynovial Giant Cell Tumor. According to GlobalData, Phase II drugs for Tenosynovial Giant Cell Tumor have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMB-051’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMB-051 overview
AMB-051 is under development for the treatment of tenosynovial giant cell tumor of the knee, advanced solid tumors such as tenosynovial giant cell tumor of the knee, pancreatic cancer, colorectal cancer, non small cell lung cancer, age related macular degeneration and polycystic kidney disease. It is administered intravenously as a concentrate for a solution. It is a fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (CSFR1).
It was also under development for the treatment of idiopathic pulmonary fibrosis and diabetic macular edema.
AmMax Bio overview
AmMax Bio (AmMax) is a biotechnology company. It develops novel therapies for the treatment of oncology diseases. The company’s product pipeline includes AMB-05X, a clinical phase mAb targeting CSF1R to treat tenosynovial giant cell tumor (TGCT); and AMB-101 and AMB-102 antibody-drug conjugates (ADC) for the treatment of solid tumors. AmMax works in collaboration with Amgen for licensing of a potent monoclonal antibody targeting CSF1R, and Evopoint Biosciences for developing ADC to address multiple solid tumors. The company conducts clinical trials and has completed various studies in patients related to TGCT. AmMax is headquartered in Redwood City, California, the US.
For a complete picture of AMB-051’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
